FDG-PET in Advanced Melanoma

NCT02236546 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2017-04-13

Study results available
· View outcomes & findings →

Summary

This clinical trial studies how well FDG-PET/CT measures early response in patients with stage III-IV melanoma who are receiving chemotherapy. Positron emission tomography (PET)/computed tomography (CT) uses a metabolic imaging radiotracer, \[18F\]fluorodeoxyglucose (FDG), which selectively accumulates in tumors. FDG-PET/CT of advanced melanoma before, during, and after treatment may improve methods for predicting which patients may benefit from therapy.

Conditions

  • Recurrent Melanoma
  • Stage IIIA Melanoma
  • Stage IIIB Melanoma
  • Stage IIIC Melanoma
  • Stage IV Melanoma

Interventions

DIAGNOSTIC_TEST

[18F]fluorodeoxyglucose

FDG is administered intravenously approximately 60 minutes prior to the start of PET image acquisition.

OTHER

Molecular assays on biopsied tissue

Correlative studies

DEVICE

positron emission tomography

Undergo FDG-PET/CT

DEVICE

computed tomography

CT that is part of FDG-PET/CT is a low-milliampere, low-resolution scan that is used for anatomic localization and attenuation correction for PET images.

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH
  • Vanderbilt-Ingram Cancer Center

    lead OTHER

Principal Investigators

  • Tom Yankeelov, PhD · Vanderbilt-Ingram Cancer Center

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2014-10-31
Completion
2015-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02236546 on ClinicalTrials.gov